Biomark will collect data for EU CE Mark certification of its biomarker for early stage colon cancer, based on a blood test.
Micromedic Technologies Ltd. (TASE:MCTC) portfolio company Biomark Ltd. has begun a clinical trial to collect data for a registration file for EU CE Mark certification of the company's innovative biomarker for early stage colon cancer, based on a blood test.
The trial is being conducted jointly with Clalit Health Services on the basis of a cooperation agreement signed in August 2010 to carry out clinical trials for early diagnosis of colon cancer. The trial will include at least 200 persons at two medical centers. Biomark believes that the collection of data will take several months, and that preliminary results will be due in the third quarter.
Micromedic owns 90% of Biomark.
Published by Globes [online], Israel business news - www.globes-online.com - on February 13, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011